EN DE
Watch Enovis Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Enovis Corp (ENOV) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Enovis Corp stock $34.24, price $27.16, upside +26.1%, quality 40 out of 100. Rating: undervalued. Calculated from audited financials with 3 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EC Enovis Corp logo Some data Nov 6, 2026

Enovis Corp

ENOV · US
Speculative

The stock costs 21% less than our calculation considers fair.

Fair value $34.24 · Undervalued
Generates free cash flow
Upbeat coverage
Profit last quarter +153% vs. a year ago.
Quality 40/100
Loss only from goodwill write-downs · -22.9% net margin (TTM) · excl. goodwill write-downs +22.6%
Moderate debt
Insiders bought $541,687 (6M)
Some data
Weak Growth (revenue 5y −6.0 %/yr in USD)
Trails peers (3/12)
Narrow moat 15/100 · thin data
Watch Enovis Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$91.17 $17.43 Fair Value $34.24 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $17.43 – $91.17 · fair‑value band $8.02 – $66.69 · the $27.16 price screens below the $34.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Enovis in your weekly email

Every Wednesday you see whether Enovis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.

Show moreShow less

The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions.

The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools.

It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients.

The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Stock analysis

Enovis Corp (ENOV) currently trades at $27.16, while our model-based Fair Value estimate is $34.24, implying the stock looks roughly 21% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $43.59 per share, and 2 of the 3 models we run sit above the $27.16 price.

Bear case: the DCF Models group reads lowest at $25.38, and 1 of the 3 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $8.02 (bear) to $66.69 (bull), the price of $27.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Enovis Corp reported revenue of $2.2B in FY2025 versus $1.4B in FY2021, a compound +12.0%/yr. Reported net income was −$1.2B in FY2025.

Key figures

Market cap $1.6B Small · P/S ratio 0.72 · EPS (TTM) $−9.23 · Net margin −22.9% · Return on equity −30.0% · Return on assets (EBIT) −4.2% (5-year average) · Operating margin 4.0% · Revenue (TTM) $2.3B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 14% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 26%, ENOV screens cheaper than that median.

Fair Value models

Bear $8.02 Fair Value $34.24 Bull $66.69
Price $27.16 · Upside +26.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
5Y EBITDA Exit $8.02 $34.24 $66.69 67
EV/EBITDA $26.87 $43.59 $60.31 66
10Y EBITDA Exit n/a $16.51 $43.68 63
All 3 models by family
DCF Models
5Y EBITDA Exit $8.02 $34.24 $66.69 67
10Y EBITDA Exit n/a $16.51 $43.68 63
Multiples
EV/EBITDA $26.87 $43.59 $60.31 66

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20
How much profit the company makes from its sales and capital
Quality Growth 45
Are margins and returns getting better?
Cashflow 21
Do the profits arrive as real cash?
Financial strength 28
Debt, balance sheet and risk of trouble
Investment 87
Does it invest with discipline instead of growing at any price?
Low Volatility 15
How calm the share price moves, does not count
Price momentum 35
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 44
Distance to the 52-week high, does not count
New shares 65
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $541,687, most recently on Sep 4, 2026. Buying cluster

  • BuyOliver EngertChief Administrative Officer11× since Feb 27, 2026: 20,458 shares, avg. $21.41$437,982Sep 4, 2026
  • BuyDamien McDonaldChief Executive Officer, Director13,035 shares at $19.15$249,620Sep 4, 2026
  • SaleDaniel A PryorFormer EVP, Strategy & Bus Dev1,665 shares at $27.21$45,298Dec 9, 2025
  • BuyJohn KlecknerPrincipal Accounting Officer2,468 shares at $30.32$74,830Nov 25, 2025

Plus 14 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.0%
Start year 2020 (pandemic). Over 10 years: −5.5% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.3% (2020) → −0.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+57.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +53.8% a year for the price and +1.9% for the forecasts.
Forecast 2026 (sales)+4.1%
Forecast 2027 (sales)+4.9%
Projected 2028 (sales)+4.5%
Projected 2029 (sales)+4.2%
Projected 2030 (sales)+3.8%

Watch ENOV, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Enovis Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside +26.1% · Top 25%
Profitability
Return on assets −30.9% · Bottom 25%
Net margin (12 months) −22.9% · Bottom 25%
Operating margin (12 months) 4.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 1.8% · Below median
Balance sheet
Debt / equity 0.85× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.05× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.68× · Cheapest 25%
Price / free cash flow (fiscal year) 78.6× · Priciest 25%
EV/EBITDA 7.2× · Cheapest 25%
PEG 1.90× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)68 · sector 6
FUTURE (revenue growth)9 · sector 36
PAST (return on equity)0 · sector 17
HEALTH (low debt)58 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs ENOV
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs ENOV
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs ENOV
DexCom, Inc DXCM $79.41 $87.35 +10% vs ENOV
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs ENOV
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs ENOV
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs ENOV
Abbott Laboratories, ABT $109.93 $75.28 −32% vs ENOV
Medtronic plc MDT $101.80 $65.61 −36% vs ENOV
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs ENOV

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Enovis Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Enovis Corp Fair Value". https://www.fairvalue-calculator.com/stock/ENOV

Frequently asked questions

Is Enovis Corp (ENOV) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $34.24 versus a price of $27.16, about +26% upside (undervalued).
What is the fair value of ENOV?
Our model-based fair value for Enovis Corp is $34.24 (as of Nov 6, 2026), built from audited fundamentals. The current price: $27.16.
What is the quality score of ENOV?
Enovis Corp has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Enovis Corp (ENOV)?
Our model-based price target is the fair value of $34.24 (as of Nov 6, 2026) from 3 valuation models. Cautious scenario $8.02, optimistic scenario $66.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Enovis Corp stock forecast for 2026?
Our models put fair value at $34.24, about +26% upside versus a price of $27.16 (undervalued). Cautious scenario $8.02, optimistic scenario $66.69. The calculation is refreshed regularly with new filings.
What is the revenue of Enovis Corp (ENOV)?
Enovis Corp reported trailing-twelve-month revenue of about $2.3B (latest available figure, as of Nov 6, 2026).
What growth is priced into Enovis Corp (ENOV)?
For today's price to be fair in a discounted-cash-flow model, Enovis Corp would have to grow free cash flow by +57.5 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -6.1 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of ENOV use?
Our models discount Enovis Corp at 12.4 %: a base by market capitalisation (small), damped by beta 1.42, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Enovis Corp that is +57.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Enovis Corp (ENOV) delivered so far?
Over the past 5 years revenue at Enovis Corp grew -6.1 % a year. The price currently implies free-cash-flow growth of +57.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Enovis Corp (ENOV) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Enovis Corp (+57.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Enovis Corp (ENOV)?
The free-cash-flow yield on the price is 1.27 %: that much free cash flow Enovis Corp produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Enovis Corp (ENOV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Enovis Corp it is $34.24 per share (as of Nov 6, 2026), against a price of $27.16. It is the blended result of 3 valuation models in 2 families (DCF Models, Multiples).
Is Enovis Corp stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ENOV trades below its calculated fair value: price $27.16, fair value $34.24, a gap of about +26% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENOV?
No. The price is what the market pays today ($27.16); the fair value is what the company's own numbers justify ($34.24). For Enovis Corp the two are $7.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Enovis Corp worth?
The market values Enovis Corp at about $1.6B (market capitalisation, as of Nov 6, 2026). Per share that is $27.16; our models calculate a fair value of $34.24 per share.
What do the bullish and bearish scenarios say about ENOV?
Our models span a range for Enovis Corp: cautious scenario $8.02, base $34.24, optimistic $66.69 per share (as of Nov 6, 2026, price $27.16). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of ENOV?
The PEG ratio of Enovis Corp is 1.90 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Enovis Corp (ENOV)?
Balance-sheet figures for Enovis Corp (as of Nov 6, 2026): return on equity −30.0%, debt of 0.85 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is ENOV from its 52-week high?
Enovis Corp trades at $27.16, about 14% below its 52-week high of $31.51 and 56% above the low of $17.43 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $34.24 is for.
Which stocks are comparable to Enovis Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Enovis Corp stock attractive at the current price?
The data as of Nov 6, 2026: price $27.16, calculated fair value $34.24 (+26%), Quality Score 40/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ENOV calculated?
We run Enovis Corp through 3 models from 2 families: DCF Models, Multiples. Every model gets the same audited fundamentals; the fair value of $34.24 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Enovis Corp currently trades 21% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Enovis Corp (ENOV)?
The closing price on Nov 6, 2026 was $27.16. Our model-based fair value is $34.24, about +26% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Enovis Corp right now?
The model range is unusually wide ($8.02 to $66.69). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Enovis Corp

How large is the market capitalisation of Enovis Corp (ENOV)?
The market capitalisation of Enovis Corp is $1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Enovis Corp (ENOV)?
The price-to-sales ratio of Enovis Corp is 0.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Enovis Corp (ENOV)?
Earnings per share at Enovis Corp are $−9.23. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Enovis Corp (ENOV)?
The net margin of Enovis Corp is −22.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Enovis Corp (ENOV)?
The return on equity (ROE) of Enovis Corp is −30.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Enovis Corp (ENOV)?
On an EBIT basis the return on assets of Enovis Corp is −4.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Enovis Corp (ENOV)?
The operating margin of Enovis Corp is 4.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Enovis Corp (ENOV)?
Revenue at Enovis Corp is growing +1.8% versus a year earlier (3y avg +12.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Enovis Corp (ENOV)?
Earnings per share at Enovis Corp are growing +153% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Enovis Corp (ENOV) carry?
The net debt of Enovis Corp is $1.3B (fiscal year 2025, ≈ 67.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Enovis Corp in the live analysis

One click puts Enovis Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.